2-FDCK (2-fluorodeschloroketamine)

A ketamine-like dissociative designer drug (2-fluorodeschloroketamine) used recreationally; not FDA-approved for medical use.

psilodex.org/m/2-fdck · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: Not stated in label or references

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “2-FDCK (2-fluorodeschloroketamine)”, v2026.10.05. psilodex.org/m/2-fdck

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

Not FDA-approved

Availability

Unregulated novel psychoactive substance; not FDA-approved

01 Interaction with psilocybin

Not studied with psilocybin; this ketamine-like drug raises blood pressure and heart rate and causes dissociation, so added effects are possible.

Detail 2-FDCK is a ketamine-like dissociative sold as a novel psychoactive substance. In a case series of 20 people exposed to 2-FDCK (usually with other ketamine analogs), the main effects were impaired consciousness, agitation, high blood pressure and fast heart rate. Five lost consciousness or had a convulsion (Tang 2020). French reports describe mainly neurological and psychiatric effects, including dissociation, and record deaths. It has not been studied with psilocybin; combined use may add dissociation, confusion and blood pressure rise. Sources [1][2][3]

Human data with psilocybin: No psilocybin data; based on how it works and its label

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

4 listed (1 possible) · counted on reports

Dissociative (NMDA antagonist): Blocks NMDA receptors and can cause dissociation: feeling detached from the body or surroundings. Effects can add to psilocybin’s. Sources [2]
Psychiatric reactions: The label or source warns of psychiatric effects such as psychosis, mania, hallucinations, suicidal thoughts or severe mood or behavior changes. Psilocybin can also bring up strong emotions, so these warnings are relevant to screening. Sources [2]
Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]
Lowers seizure threshold or carries seizure riskPossible: Makes a seizure more likely, or has been linked to seizures.Possible: The source describes the effect as small, seen only in laboratory or animal studies, or theoretical. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Tang MHY, Li TC, Lai CK, et al. Emergence of new psychoactive substance 2-fluorodeschloroketamine: toxicology and urinary analysis in a cluster of patients exposed to ketamine and multiple analogues. Forensic Sci Int 2020;312:110327. — Raises blood pressure or heart rate: Abstract "The clinical effects observed in patients exposed to 2F-DCK are predominantly neurological (impaired consciousness, agitation, abnormal behaviour) and cardiovascular (hypertension, tachycardia)" | Lowers seizure threshold or carries seizure risk: Abstract "five patients had loss of consciousness or convulsion"
Mezaache S, Pochard L, Peyrière H, et al. Emerging new psychoactive ketamine analogues: patterns of use and health risks identified by the French Addictovigilance Network. Int J Drug Policy 2026;153:105326. — Dissociative (NMDA antagonist): Abstract "Ketamine analogues are emerging dissociative substances structurally related to ketamine" | Psychiatric reactions: Abstract "Adverse effects were mainly neurological and psychiatric, including dissociation and impaired consciousness."
Riess S, Chèze M, Muckensturm A, et al. 2-Fluorodeschloroketamine consumption: about two deaths and a case of self-mutilation. J Anal Toxicol 2024;48(5):398–404. — Abstract: "We report here a case of self-mutilation (Case 1) and two forensic deaths linked to 2-FDCK consumption."

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →